This article is more than 5 years old. Information may no longer be current.
iStar completes enrollment in MINIject MIGS trial
Click Here to Manage Email Alerts
Enrollment has been completed in the first in-human trial for iStar’s microinvasive MINIject glaucoma surgery device, according to a company press release.
The MIGS device will be tested in 25 patients with mild to moderate open-angle glaucoma that is not controlled by topical hypotensives in a prospective, international study. The trial will assess the safety and performance of the device as measured by IOP reduction at 6 months, the release said.
iStar’s MINIject uses “soft and flexible, medical grade silicone which conforms to the eye anatomy,” promoting “biointegration of surrounding tissue into the material” and preserving drainage, according to the release.
The device facilitates aqueous outflow to the suprachoroidal space and is implanted in a one-step procedure, the release said.
Source: www.istarmed.com